Clinical Trial Update: Pilot Study of Autologous Anti-EGFRvIII CAR T Cells in Recurrent Glioblastoma Multiforme [Phase 1]

View source ↗

Summary

Phase 1 pilot study evaluating autologous anti-EGFRvIII CAR T cells in recurrent glioblastoma; the document notes the trial status but provides no results.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Glioblastoma

Drugs mentioned

• Autologous anti-EGFRvIII CAR T cells (EGFRvIII-targeted CAR T cells)

Snippet

Sponsor: Beijing Sanbo Brain Hospital | Conditions: Glioblastoma Multiforme | Phase 1 | Status: UNKNOWN